Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Clinical trial NCT06191263 · RECRUITING

Trial details

NCT number: NCT06191263
Sponsor: Ryvu Therapeutics SA
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2024-01-05
Primary completion: 2026-02-01
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.